Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype.
about
Implementing genotype-guided antithrombotic therapy.Association of CYP2C19*2 and *3 genetic variants with essential hypertension in KoreansAllele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population.Allele and genotype frequency of CYP2C19 in a Tamilian population.Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy SwedesGenetic polymorphisms and phenotypic analysis of drug-metabolizing enzyme CYP2C19 in a Li Chinese population.Allele and genotype frequencies of CYP2B6 and CYP2C19 polymorphisms in Egyptian agricultural workers.Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects.Genotype‑phenotype analysis of CYP2C19 in the Tibetan population and its potential clinical implications in drug therapyThe role of african american ethnicity and metabolism in sentinel polychlorinated biphenyl congener serum levelsCYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factorsGenotype-phenotype analysis of CYP2C19 in healthy saudi individuals and its potential clinical implication in drug therapy.Inhibition of the active principle of the weak opioid tilidine by the triazole antifungal voriconazoleCytochrome P450 pharmacogenetics in African populations.High prevalence of CYP2C19*2 allele in Roma samples: study on Roma and Hungarian population samples with review of the literature.Cytochrome P450 pharmacogenetics in African populations: implications for public health.Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.Genetic polymorphisms of the drug-metabolizing enzyme CYP2C19 in the Uyghur population in northwest China.Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China.Genetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent.Genetic Polymorphism of Cytochrome p450 (2C19) Enzyme in Iranian Turkman Ethnic Group.Omeprazole limited sampling strategies to predict area under the concentration-time curve ratios: implications for cytochrome P450 2C19 and 3A phenotyping.CYP2C19- and CYP3A4-dependent omeprazole metabolism in West Mexicans.Lack of weight-based dose dependency and intraindividual variability of omeprazole for CYP2C19 phenotyping.Genetic polymorphisms and novel allelic variants of CYP2C19 in the Chinese Han population.Analysis of CYP2C19 Genetic Polymorphism in a Large Ethnic Hakka Population in Southern China.Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.Prevalence of the CYP2C19*2 (681 G>A), *3 (636 G>A) and *17 (‑806 C>T) alleles among an Iranian population of different ethnicities.Prevalence of CYP2C19 Genetic Polymorphism among Normal People and Patients with Hepatic Diseases.
P2860
Q33990428-1E6AC8CE-35B6-49B6-80A2-8215B34ABE3BQ34306561-D8A4C5A1-77F4-4593-BB9C-81BDFCB03A50Q35803786-32BB3521-91A1-49E1-BA46-43CF8F6B6970Q35825705-54911789-DA33-48E8-8D9C-9C8C604333C1Q35825761-F1C5D41E-2B4A-41B7-BD29-EDFD8C3B6CF8Q36375369-040482A5-654F-448B-BB7E-AD5D15E49303Q36406247-79892711-76BE-4563-937E-FF752CE49FD5Q36475190-194FEB99-04BE-44C4-BD73-C1A8AA08D6DCQ36624080-D1BA0835-3589-4D78-984D-C5CF9C71DD06Q37089317-757B0DA1-5E6A-4BBB-A0DC-D17563650EB2Q37140633-159D7A1C-3C40-44BC-8CB1-02F53A9985E6Q37176949-8C1A789C-5EB6-4921-AF7A-2AB4EDAE3901Q37471073-672C923A-B48B-4833-B552-CC28EE82EEEFQ38099372-9A5390CD-D4B6-4680-91D8-180FB3EAACC5Q38104273-F4B6016B-BCF3-4A12-9554-ECEC573A36B9Q38192688-2C2C79F1-6E3E-44B0-B405-98DA4EC8D905Q38616806-74FF3D14-89C2-42CF-A4AD-206D5DA5B585Q38947127-B6B2F16A-D99A-4FF7-87F8-116D0AFD8E59Q40085185-12FF2707-47DB-40A4-A349-91C5383D9C23Q41595607-ED20501F-8312-4CBD-83B4-C6582124302DQ43071574-BD41C4C5-B920-495B-9D39-34B138BB60D1Q43626046-FFD651D9-C3BF-4469-9373-746938413934Q44613016-E3CA184B-D5D4-44A4-8EE4-B5528805D24DQ45022878-BB2298AC-4217-4807-8A19-5D24B348A139Q45821926-21BCAAA1-12ED-49B1-8E10-043AFCA5AF3FQ47231767-1A14C96E-B6C6-4D6C-A2B5-AC7FA470DF21Q49833189-B84550A3-C10F-4FF3-943E-4FBD2B492560Q50067945-68D26E8C-D9FD-48C1-BAC6-DC6C11624AD0Q54257248-5004B4FD-E655-45F7-AA86-2AF7273599F1
P2860
Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Bantu Tanzanians have a decrea ...... ion to their CYP2C19 genotype.
@en
Bantu Tanzanians have a decrea ...... ion to their CYP2C19 genotype.
@nl
type
label
Bantu Tanzanians have a decrea ...... ion to their CYP2C19 genotype.
@en
Bantu Tanzanians have a decrea ...... ion to their CYP2C19 genotype.
@nl
prefLabel
Bantu Tanzanians have a decrea ...... ion to their CYP2C19 genotype.
@en
Bantu Tanzanians have a decrea ...... ion to their CYP2C19 genotype.
@nl
P2093
P2860
P1476
Bantu Tanzanians have a decrea ...... ion to their CYP2C19 genotype.
@en
P2093
A Wennerholm
A Y Massele
I Johansson
L Bertilsson
P2860
P304
P356
10.1016/S0009-9236(98)90070-4
P407
P577
1998-10-01T00:00:00Z